Lantus is an analogue insulin produced by Sanofi-Aventis with the medical name insulin glargine. Lantus has been available for pharmaceutical use since the year 2000. Lantus hit the news in June 2009 ...

Lantus can interact with several types of drugs, including metoprolol (Toprol XL), semaglutide (Ozempic), and olanzapine (Zyprexa). These interactions can lead to an increased risk of hypoglycemia or ...

The FINANCIAL — Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced on September 20 results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting ...

Today, Sanofi-aventis announced the results of new analysis that found a significantly lower risk of nocturnal hypoglycemia with Lantus (insulin glargine [rDNA] injection) as compared to NPH insulin.

Lantus (insulin glargine) is a brand-name subcutaneous injection that’s prescribed for diabetes. It’s used in adults and some children. The cost of the drug with and without insurance can depend on ...

Sanofi has inaugurated a new assembling and packaging line to produce its flagship pre-filled insulin injection pen Lantus SoloSTAR at its Beijing plant located at the Beijing Economic-Technological ...